Levetiracetam for Benign Rolandic Epilepsy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-03-31

Study Completion Date

2006-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to test if the language problems commonly seen in children with benign rolandic epilepsy would improve by switching anticonvulsants to levetiracetam.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children

NCT01521130

Benign Childhood Epilepsy With Centro-Temporal Spikes

COMPLETED PHASE1

Efficacy and Safety of Levetiracetam in Routine Clinical Practice in Czech and Slovak Republics, Hungary, and Romania.

NCT00614549

Epilepsy

COMPLETED

Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures

NCT00152516

Epilepsy, Partial

COMPLETED PHASE3

Effect of Levetiracetam on Brain Excitability

NCT00006191

Healthy Myoclonic Epilepsy

COMPLETED

Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia

NCT02199509

Oromandibular Dystonia Cranial Dystonia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 6 month study in which children on another anticonvulsant would have EEG, language testing, and a clinic visit at baseline. They would then be rapidly transitioned off of their current anticonvulsant and onto levetiracetam (Keppra). Repeat EEG and language testing would be done after 6 months to evaluate for improvement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Levetiracetam

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 6-12
* Benign rolandic epilepsy
* Language difficulties as reported by parents or teachers
* On another anticonvulsant other than levetiracetam

Exclusion Criteria

* Prior use of levetiracetam
* On 2 or more anticonvulsants
* Language problems prior to epilepsy
* Another seizure disorder
* Status epilepticus within the past 6 months
* Significant psychiatric disease
* Progressive neurologic disease

Minimum Eligible Age

6 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No